1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
James Li
James Li
Articles (1292)  | Author's Website |

5 Greenblatt Magic Formula Biotech Stocks to Weather the Summer Coronavirus Storm

Stocks to consider as biotech company Novavax gets $1.6 billion in federal aid for Covid-19 vaccine

In light of Novavax Inc. (NASDAQ:NVAX) getting $1.6 billion in federal aid for its coronavirus vaccine candidate, investors might find opportunities in biotechnology stocks that have high financial strength, earnings yield and return on capital. The top five stocks according to the Joel Greenblatt Magic Formula Screen, a Premium value screen, are Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), Novo Nordisk A/S (NYSE:NVO), Galapagos NV (NASDAQ:GLPG), Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Vertex Pharmaceuticals Inc. (NASDAQ:VRTX).

Novavax continues big surge on coronavirus vaccine federal aid

Shares of the Gaithersburg, Maryland-based company closed at $104.56, close to a 52-week high of $111.77 and up 31.62% from the previous close of $79.44, on its announcement that the company has been selected to participate in Operation Warp Speed, a U.S. program that aims to develop a coronavirus vaccine in 2021. The stock has climbed over 1,800% year to date, from a 52-week low of around $3.98.

077bc3bf8aded45e441065e4c0a17b40.png

Novavax President and CEO Stanley Erck said in an statement that the company plans to conduct Phase 3 clinical trials of NVX-Cov2373, its vaccine candidate, and deliver up to 100 million doses by the end of this year. U.S. Health and Human Services Secretary Alex Azar added that adding Novavaxs vaccine candidate to Operation Warp Speeds portfolio increases the chance of having a safe, effective vaccine by the end of 2020.

As such, investors might seek opportunities among biotech companies that have high financial strength, strong earning yields and returns on capital. Greenblatt, manager of Gotham Asset Management, developed a magic formula where the top-ranked stocks have high Ebit-to-enterprise-value ratios and high Ebit-to-fixed-asset ratios.

Alexion

Boston-based Alexion develops and markets drugs for medical conditions like paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and generalized myasthenia gravis. GuruFocus ranks the companys financial strength 7 out of 10, driven by a high Altman Z-score of 3.73 and Piotroski F-score of 8, suggesting strong business operations.

2030f30ef85f4f5835957707551f7c62.png

Alexions Greenblatt earnings yield and return on capital are outperforming over 95% of global competitors. Such metrics, coupled with expanding operating margins and a three-star business predictability rank, contribute to a GuruFocus profitability rank of 9.

6ae0488c05fc7fe2c502cf90d53b29a1.png

Gurus with holdings in Alexion include Jim Simons (Trades, Portfolio) Renaissance Technologies, Pioneer Investments (Trades, Portfolio) and Steven Cohen (Trades, Portfolio)s Point72 Asset Management.

3f1a4cbbd6a7a980750f2864b15d49bf.png

Novo Nordisk

Danish biotech company Novo Nordisk manufactures and markets a wide range of insulins and other diabetes treatments. GuruFocus ranks the companys financial strength 8 out of 10, driven by strong interest coverage, a double-digit Altman Z-scoreand a debt-to-Ebitda ratio that outperforms over 90% of global competitors.

8ce31172835a77fe5fee5ce6912aec04.png

Novo Nordisks profitability ranks 9 out of 10 on positive investing signs like expanding operating margins, a five-star business predictability rank, a Greenblatt earnings yield that outperforms 93.20% of global competitors and a Greenblatt return on capital that outperforms 95.54% of global peers.

3ac11c059723282031317034a8ff94ee.png

Gurus with holdings in Novo Nordisk include Ken Fisher (Trades, Portfolio) and Tom Gayner (Trades, Portfolio).

5054f2bbe2c2054ac7566bd1b1b00a4d.png

Galapagos NV

Galapagos discovers and develops small-molecule medicines for the treatment of rheumatoid arthritis, Crohns disease, ulcerative colitis and cystic fibrosis. GuruFocus ranks the Belgian clinical-stage biotech companys financial strength 8 out of 10 on the back ofcash-to-debt and debt-to-equity ratios outperforming over 81% of global competitors.

bbcef1c7a1e8f1407e83de76dcee7d0b.png

Galapagos Greenblatt earnings yield and return on capital are outperforming 90.04% and 98.07% of global competitors.

4b9904b36bbf69cd7471c8e371acae05.png

Regeneron

Regeneron develops and commercializes products for the treatment of eye diseases, cardiovascular disease, cancer and inflammation. GuruFocus ranks the Tarrytown, New York-based companys financial strength and profitability 8 out of 10 on several positive investing signs, which include robust interest coverage, a double-digit Altman Z-score and expanding operating margins.

b05c70ee518e33c868d14eb6f77b678b.png

Regenerons Greenblatt earnings yield and return on capital are outperforming 92.39% and 93.61% of global competitors.

376cebc91d8aa8aab2fdc49598e0c021.png

Regeneron announced on Tuesday that, as part of Operation Warp Speed, the Biomedical Advanced Research and Development Authority and the U.S. Department of Defense awarded the company a $450 million contract to manufacture Regenerons investigational double antibody cocktail for the treatment of Covid-19. The companys shares closed at $640.88, up 2.17% from the previous close of $627.25.

c4d8f657ff7f6afc6a5b57c6d0736d35.png

Vertex

Boston-based Vertex discovers and develops small-molecule drugs for the treatment of cancer, pain, inflammatory diseases, influenza and other rare diseases. GuruFocus ranks the companys financial strength 8 out of 10 on the back of double-digit Altman Z-scores and debt ratios outperforming over 70% of global competitors.

99219a196fd35b7300e65889e94a0614.png

Disclosure: No positions.

Read more here:

Not a Premium Member of GuruFocus? Sign up for afree 7-day trial here.

About the author:

James Li
I am an editorial researcher at GuruFocus. I have a Master's in Finance from SMU, and I enjoy writing reports on financial trends and investor portfolios. Follow me on Twitter at @JamesLiGuru!

Visit James Li's Website


Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:



Performances of the stocks mentioned by James Li


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)